Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Semin Thromb Hemost. 2010 Jul;36(5):498-509. doi: 10.1055/s-0030-1255444. Epub 2010 Jul 14.

Recombinant factor IX for clinical and research use.

Author information

  • 1Department of Pediatrics, Gene Therapy Center, Harold R. Roberts Comprehensive Hemophilia Treatment Center, University or North Carolina at Chapel Hill, Chapel Hill, NC 27599-7236, USA. Paul_Monahan@med.unc.edu

Abstract

The last significant advance in the therapy of hemophilia B was the introduction of recombinant factor IX (FIX), ensuring an advanced level of safety from potential infectious contaminants of plasma-derived clotting factors. Since that time, recombinant DNA techniques have been applied in research to elucidate the role of FIX and its functional domains within coagulation. At the same time, recombinant DNA technology has been applied to engineer an expanding spectrum of novel FIX therapies that are now being translating into clinical trials. The experience with the existing recombinant FIX product is reviewed with a focus on the novel products and the potential to improve the quality of life for individuals with hemophilia B.

PMID:
20632248
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Georg Thieme Verlag Stuttgart, New York
    Loading ...
    Write to the Help Desk